CD4 News and Research

RSS

HIV-positive patients have higher incidence of non-melanoma skin cancers

HIV-positive patients have a higher incidence of non-melanoma skin cancers, according to a Kaiser Permanente study that appears in the current online issue of the Journal of the National Cancer Institute. Specifically, basal cell and squamous cell carcinomas occur more than twice as often among HIV-positive individuals compared to those who are HIV-negative.

30 Jan 2013

Current smokers with HIV more likely to get bacterial pneumonia

Bacterial pneumonia is one of the commonest and most serious infections occurring in people infected with HIV. A metanalysis of cohort and case control studies published in BioMed Central's open access journal BMC Medicine finds that current smokers with HIV were at double the risk of bacterial pneumonia than non-smoking counterparts, but that when people stopped smoking their risk was reduced.

21 Jan 2013

Early treatment during primary HIV infection shows promise

Two papers in The New England Journal of Medicine suggest that starting antiretroviral treatment early after HIV infection is diagnosed may improve patients’ immune response, boosting the initial recovery of the immune system and delaying progression of the disease.

21 Jan 2013

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

A research team led by the La Jolla Institute for Allergy & Immunology has discovered the mechanism that enables CD4 helper T cells to assume the more aggressive role of killer T cells in mounting an immune attack against viruses, cancerous tumors and other damaged or infected cells.

21 Jan 2013

Mature CD4+ helper T lymphocytes can be re-programed to gain killing functions

The fate of mature T lymphocytes might be a lot more flexible than previously thought. New research from the RIKEN Center for Allergy and Immunology (RCAI) in Japan and La Jolla Institute for Allergy and Immunology (LIAI) in the USA shows for the first time that mature CD4+ helper T lymphocytes can be re-programed to become killer-like CD8+ T lymphocytes and gain killing functions.

21 Jan 2013

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection.

16 Jan 2013

Vaccine gives HIV patients a long-term boost

A functional cure for HIV-1 seems feasible after research shows that an immunotherapeutic vaccine demonstrated long-term efficacy at reducing viral load when administered to patients in the early stages of disease.

7 Jan 2013

Crofelemer receives FDA approval for treatment of HIV associated diarrhea

Glenmark Pharmaceuticals Limited announced today that the US Food and Drug Administration has provided Marketing approval to its partner in US, Salix Pharmaceuticals Limited, for Crofelemer 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in patients with human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART).

2 Jan 2013

Insights into tissue-based T cells

US researchers have, for the first time, characterized T cells located in human tissues, rather than in the blood.

31 Dec 2012

Lymphocyte clue to multiple sclerosis drug response

Patients with rapid recovery of CD4-positive T cells after alemtuzumab treatment for multiple sclerosis are at risk for disease progression or relapse, research suggests.

18 Dec 2012

SLU researchers to study physiological and biochemical functions in lupus

Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.

14 Dec 2012

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

A clinical trial will examine an investigational drug's early bacteria-killing activity in patients newly diagnosed with drug-sensitive pulmonary tuberculosis.

12 Dec 2012

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Children with HIV more likely to develop atherosclerosis

Children with HIV have a 2.5 fold increased risk of atherosclerosis, according to research presented at EUROECHO and other Imaging Modalities 2012. Antiretroviral treatment, lipid lowering drugs and prevention with healthy lifestyles are needed to prevent early death from cardiovascular disease.

5 Dec 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Inovio Pharmaceuticals, Inc. announced today that testing of multiple synthetic vaccine constructs for cytomegalovirus (CMV) induced robust T cells in mice, demonstrating the potential for a SynCon DNA vaccine to treat this virus that causes infant death and congenital abnormalities, is associated with cerebral palsy and brain tumors, and is the most common viral infection in organ transplant recipients. CMV is also associated with numerous inflammatory diseases and cancers, and is implicated in hypertension, a major risk factor for cardiovascular diseases.

26 Nov 2012

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia is when you lack the T cells of your immune system. T cells are very important for controlling infection. Probably the most known cause of lymphopenia is HIV.

23 Nov 2012

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

Immunomic Therapeutics, Inc., a leader in developing novel allergy immunotherapies, announced today that it has dosed the first patient in a Phase I clinical trial of its lead candidate, JRC-LAMP-vax vaccine, at its clinical site in Honolulu, Hawaii. Initial subjects include Japanese ex-patriates previously exposed to Japanese red cedar, or "Sugi," as it is known in Japan.

9 Nov 2012

NJH researchers discover novel target for treatment of food allergies

Researchers at National Jewish Health have discovered a novel target for the treatment of food allergies. Erwin Gelfand, MD, and his colleagues report in the October 2012 issue of the Journal of Allergy and Clinical Immunology that levels of the enzyme Pim 1 kinase rise in the small intestines of peanut-allergic mice. Inhibiting activity of Pim 1 markedly reduced the allergic response to peanuts.

2 Nov 2012

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

To support their research for a vaccine against the HI-Virus, Prof. Dr. Klaus Überla of the Faculty for Medicine at the Ruhr-Universität Bochum and his research team will receive $2.3 million in funding within the next three years from the Bill & Melinda Gates Foundation. The scientists are part of the Collaboration for AIDS Vaccine Discovery (CAVD), which seeks to speed up the development of an HIV-vaccine through a rigorous exchange of information, methods and reagents.

29 Oct 2012

CD4 News and Research

HIV-positive patients have higher incidence of non-melanoma skin cancers

Current smokers with HIV more likely to get bacterial pneumonia

Early treatment during primary HIV infection shows promise

Scientists identify new mechanism that turns CD4 helper T lymphocytes into killer cells

Mature CD4+ helper T lymphocytes can be re-programed to gain killing functions

Experimental vaccine elicits antibodies that can protect against Ebola virus infection

Vaccine gives HIV patients a long-term boost

Crofelemer receives FDA approval for treatment of HIV associated diarrhea

Insights into tissue-based T cells

Lymphocyte clue to multiple sclerosis drug response

SLU researchers to study physiological and biochemical functions in lupus

Clinical trial to examine AstraZeneca experimental drug against pulmonary tuberculosis

Janssen announces U.S. prescribing information update for EDURANT tablets

Children with HIV more likely to develop atherosclerosis

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

Inovio's SynCon DNA vaccine effective at inducing CD8+ T cell responses specific to CMV

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Immunomic Therapeutics initiates JRC-LAMP-vax vaccine Phase I trial in Sugi allergy

NJH researchers discover novel target for treatment of food allergies

RUB-medical researchers receive $2.3M Gates Foundation grant for HIV vaccine research

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News